'Not been pretty': Novo Nordisk faces rare shareholder rebuke over board shake-up

Core Viewpoint - Novo Nordisk is facing a backlash from minority shareholders who are preparing to protest against a board restructuring initiated by its dominant shareholder [1] Group 1: Shareholder Dynamics - Minority investors are organizing a protest vote against the board changes [1] - The restructuring was driven by the company's dominant shareholder, indicating potential governance issues [1] Group 2: Company Background - Novo Nordisk is a Danish pharmaceutical company known for its diabetes and obesity treatments [1]